MORAb-009 is a IgG1 antibody that recognizes a cell surface glycoprotein, mesothelin, which is over-expressed on a number of cancers, including pancreatic, ovarian, lung, and colorectal cancer. Researchers at the National Cancer Institute (NCI) and the Johns Hopkins University have independently validated the association of this antigen in cancer and its potential for cancer therapy by using immuno-based therapies.

MORAb-009 is currently being developed as a therapeutic antibody for the treatment of pancreatic cancer and mesothelioma. An Investigational New Drug (IND) application was opened for MORAb-009 in 2006. A Phase I study in patients with mesothelin-positive cancers conducted at Johns Hopkins, Fox Chase Cancer Center and the National Cancer Institute showed the antibody to be well tolerated. A multi-institutional Phase II Study is currently being conducted to evaluate MORAb-009 in subjects with pancreatic cancer. For more information click here.